Takeda Pharmaceutical Co Ltd 2025 SR
The report details Takeda's environmental, social, and governance (ESG) performance for the fiscal year ended March 31, 2025. Key achievements include a 55% reduction in Scope 1 and 2 greenhouse gas emissions from a FY2016 baseline, surpassing the company's 40% target. Additionally, Takeda achieved a 7% absolute reduction in Scope 3 emissions from its FY2022 baseline and diverted 75% of its waste from landfills. On the social front, the company maintained a 100% manufacturing quality rate and enrolled 1,975 patients in its affordability-based Patient Assistance Programs in low- and middle-income countries.
Company: Takeda Pharmaceutical Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2025
Type: SR
Pages: 71
Back to company
Takeda Pharmaceutical Co Ltd
ESG Databook
The report details Takeda's environmental, social, and governance (ESG) performance for the fiscal year ended March 31, 2025. Key achievements include a 55% reduction in Scope 1 and 2 greenhouse gas emissions from a FY2016 baseline, surpassing the company's 40% target. Additionally, Takeda achieved a 7% absolute reduction in Scope 3 emissions from its FY2022 baseline and diverted 75% of its waste from landfills. On the social front, the company maintained a 100% manufacturing quality rate and enrolled 1,975 patients in its affordability-based Patient Assistance Programs in low- and middle-income countries.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Apr 1, 2024 - Mar 31, 2025
Fiscal Year
2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Women in Management
Workplace Fatalities